CANSINOBIO has released its 2025 Environmental, Social and Governance (ESG) & Sustainability Report, detailing progress on climate action, product innovation and corporate governance.
Environmental performance improved markedly. Greenhouse-gas emissions per square metre of production and auxiliary space fell 17.39% year on year, while energy-consumption intensity declined 5.31%. Wastewater-pollutant discharge intensity dropped 76.47%, and non-hazardous waste intensity fell 38.46%. Total spending on environmental protection reached RMB 2.43 million, financing four compliance-upgrade projects. The company has committed to trim both energy and GHG intensities by 10% from the 2023 baseline by 2030.
R&D investment totalled RMB 371 million and supported a 273-strong research team, 55.68% of whom hold master’s degrees or higher. Four new patents were granted during the year, taking the portfolio to 57. Product highlights included NMPA approval and domestic rollout of the 13-valent pneumococcal conjugate vaccine iPneucia®, overseas launch of quadrivalent meningococcal conjugate vaccine Menhycia® following Indonesian Halal certification, and clinical progress on recombinant polio and inhaled tuberculosis vaccines. The firm also advanced a 24-valent pneumococcal candidate and a DTcP-Hib-MCV4 combination vaccine.
On the social front, women comprised 52.47% of total staff and 44.83% of management. Training coverage reached 100%, averaging 34.48 hours per employee, and no work-related fatalities were recorded. Total employee-benefit spending amounted to RMB 73.12 million.
Governance systems were strengthened. CANSINOBIO passed surveillance audits for ISO 37301 (Compliance Management) and ISO 37001 (Anti-Bribery). All employees completed compliance and anti-corruption training, and 100% of suppliers signed integrity and confidentiality agreements. No corruption or unfair-competition cases were reported. The company’s ESG governance is overseen by the Board, supported by an Audit Committee and a cross-functional working group.
Recognitions in 2025 included placement in the S&P Global Sustainability Yearbook (China Edition) and Aon’s “China Best ESG Employer” award. CANSINOBIO reiterates its goal of aligning vaccine innovation with global public-health needs while pursuing low-carbon, transparent and inclusive growth.
Comments